Nanoform Finland Plc is a biotechnology company that specializes in innovative drug delivery solutions. Its primary function is to enhance the bioavailability and efficacy of pharmaceutical compounds through its proprietary nanoparticle technology. This company operates in the healthcare and pharmaceutical sectors, providing services that aim to improve the formulation properties of drugs, leading to enhanced therapeutic outcomes. Nanoform's technology is pivotal for the development of insulin medications, cancer therapies, and various small molecule drugs, as it allows for the production of nanoparticles that can facilitate drug delivery in new and groundbreaking ways. Within the financial market, Nanoform Finland Plc plays a significant role as an innovator, offering cutting-edge solutions that address critical challenges in drug formulation and delivery. By optimizing pharmaceutical ingredients' properties, Nanoform assists pharmaceutical companies in overcoming solubility issues, thereby potentially reducing the time and cost of bringing new drugs to market. Founded in Helsinki, Finland, the company not only contributes to advancements in drug delivery but also to the broader field of nanotechnology in medicine.